BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc. (Nasdaq: HLXB) filed a Form 424B3 prospectus with the Securities and Exchange Commission on May 13, 2026. Form 424B3 is a final or supplemental prospectus type frequently associated with post-combination resale registrations in the SPAC market, reflecting activity in the later stages of a blank-check deal life cycle. The company is active in the oncology and life sciences sector, focused on cancer therapeutics development. Sponsor details and the original IPO vintage were not captured in the available filing metadata. For the full deal profile, sponsor history, and real-time filing alerts on HLXB and the broader SPAC universe, sign up for a free account at SpacDesk.